Literature DB >> 16759680

Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date.

P Faísca1, D Desmecht.   

Abstract

Biologically speaking, Sendai virus (SeV), the murine parainfluenza virus type 1, is perceived as a common respiratory pathogen that is endemic in many rodent colonies throughout the world. Currently it is believed that SeV is the leading cause of pneumonia in mice and together with the mouse hepatitis viruses, is the most prevalent and important of the naturally occurring infections of mice. The scientific community also considers SeV as the archetype organism of the Paramyxoviridae family because most of the basic biochemical, molecular and biologic properties of the whole family were derived from its own characteristics. Recently, scientific interest for this old pathogen has re-emerged, this time because of its potential value as a vector for gene transfer. This review aimed at drawing an exhaustive picture of this multifaceted pathogen.

Entities:  

Mesh:

Year:  2006        PMID: 16759680     DOI: 10.1016/j.rvsc.2006.03.009

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  35 in total

1.  HIPK2 is necessary for type I interferon-mediated antiviral immunity.

Authors:  Lili Cao; Guang Yang; Shandian Gao; Chunxia Jing; Ruth R Montgomery; Yuxin Yin; Penghua Wang; Erol Fikrig; Fuping You
Journal:  Sci Signal       Date:  2019-03-19       Impact factor: 8.192

2.  Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway.

Authors:  Suruchi N Schock; Neha V Chandra; Yuefang Sun; Takashi Irie; Yoshinori Kitagawa; Bin Gotoh; Laurent Coscoy; Astar Winoto
Journal:  Cell Death Differ       Date:  2017-01-06       Impact factor: 15.828

3.  Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging study.

Authors:  Crystal W Burke; Mei Li; Julia L Hurwitz; Peter Vogel; Charles J Russell
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

4.  Quantitation of acute phase proteins and protein electrophoresis in monitoring the acute inflammatory process in experimentally and naturally infected mice.

Authors:  Carolyn Cray; David G Besselsen; Jody L Hart; David Yoon; Marilyn Rodriguez; Julia Zaias; Norman H Altman
Journal:  Comp Med       Date:  2010-08       Impact factor: 0.982

5.  Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut.

Authors:  Rajeev Rudraraju; Sherri Surman; Bart Jones; Robert Sealy; David L Woodland; Julia L Hurwitz
Journal:  Virology       Date:  2011-01-11       Impact factor: 3.616

6.  Granzyme B regulates antiviral CD8+ T cell responses.

Authors:  Suzan M Salti; Erin M Hammelev; Jenny L Grewal; Sreelatha T Reddy; Sarah J Zemple; William J Grossman; Mitchell H Grayson; James W Verbsky
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

7.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

8.  Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice.

Authors:  Laura E Luque; Olga A Bridges; John N Mason; Kelli L Boyd; Allen Portner; Charles J Russell
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 9.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

Review 10.  Development of replication-competent viral vectors for HIV vaccine delivery.

Authors:  Christopher L Parks; Louis J Picker; C Richter King
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.